<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Ostrich</title>
	<atom:link href="http://www.tapanray.in/tag/ostrich/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Leading Through The Challenge Of Change: Is Pharma Leadership Too Archaic?</title>
		<link>http://www.tapanray.in/leading-through-the-challenge-of-change-is-pharma-leadership-too-archaic/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=leading-through-the-challenge-of-change-is-pharma-leadership-too-archaic</link>
		<comments>http://www.tapanray.in/leading-through-the-challenge-of-change-is-pharma-leadership-too-archaic/#comments</comments>
		<pubDate>Mon, 16 Jun 2014 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[archaic]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[eclectic]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[inclusive]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[Michael]]></category>
		<category><![CDATA[mode]]></category>
		<category><![CDATA[Motors]]></category>
		<category><![CDATA[Ostrich]]></category>
		<category><![CDATA[owner]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[promoter]]></category>
		<category><![CDATA[prontosil]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Rsy]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Soman.]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tesla]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5512</guid>
		<description><![CDATA[A recent major global survey titled “Testing The Health Of The Pharmaceutical Industry” has revealed that a sizable majority of executives polled, though believe the sector is in good shape, are concerned of its reputation. Interestingly, 73 percent of respondents believe &#8230; <a href="http://www.tapanray.in/leading-through-the-challenge-of-change-is-pharma-leadership-too-archaic/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/leading-through-the-challenge-of-change-is-pharma-leadership-too-archaic/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The issue of ‘Counterfeit Drugs’ in India: An “Ostrich Syndrome’</title>
		<link>http://www.tapanray.in/the-issue-of-counterfeit-drugs-in-india-an-ostrich-syndrome/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-issue-of-counterfeit-drugs-in-india-an-ostrich-syndrome</link>
		<comments>http://www.tapanray.in/the-issue-of-counterfeit-drugs-in-india-an-ostrich-syndrome/#comments</comments>
		<pubDate>Mon, 14 Feb 2011 00:30:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ACTA]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Dubai]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[hazard]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[issue]]></category>
		<category><![CDATA[menace]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Ostrich]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[related]]></category>
		<category><![CDATA[Syndrome]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[trademark]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=302</guid>
		<description><![CDATA[Ellen‘t Hoen, former Policy Advocacy Director of MSF’s Campaign for Access to Essential Medicines wrote in April 2009 as follows: “People often seem to confuse counterfeit, substandard and generic medicines – using the terms interchangeably. But they are very separate &#8230; <a href="http://www.tapanray.in/the-issue-of-counterfeit-drugs-in-india-an-ostrich-syndrome/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-issue-of-counterfeit-drugs-in-india-an-ostrich-syndrome/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
